GTI Archives - Green Market Report

Debra BorchardtMay 5, 2022
Rise.png?fit=682%2C384&ssl=1

4min6070

After the market closed on Wednesday, Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) reported its financial results for the first quarter ending March 31, 2022, with revenue rising 25% year-over-year to $243 million. This was flat compared Green Thumb’s fourth quarter of 2021, but it beat the Yahoo Finance average estimate for earnings of $236 million.

GTI also reported that its net income for the first quarter was $28.9 million or $0.12 per basic and diluted share, compared to a net income of $10.4 million, or $0.05 per basic and diluted share in the prior year. This beat the Yahoo Finance average analyst estimate for earnings of $0.06.

“Our team delivered solid first-quarter results with revenue increasing 25% over the prior-year quarter. We generated our seventh consecutive quarter of positive net income of $29 million, or $0.12 per share, and Adjusted Operating EBITDA of $67 million. For the ninth consecutive quarter, we delivered positive cash flow from operations, which was $55 million in the first quarter,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “We continue to have strong conviction in our core thesis and given the opportunity ahead, we will invest in markets where we know demand is coming. As I have said before, growth is not linear and there will be quarter-to-quarter fluctuations depending on when new markets open to adult-use sales as well as the timing of our infrastructure investments. Our preparations in New Jersey positioned us well for demand on Day One, and we feel confident in our playbook for future adult-use transitions.”

Same-Store Sales Fall

GTI said that retail revenue decreased by less than 1% quarter-over-quarter. Comparable sales growth (stores opened at least 12 months) were down 3% on a base of 51 stores. Sequential quarter-over-quarter comparable sales were down 6% on a base of 65 stores.

Still, the company continues to invest for the future even as it faces pricing pressures and rising costs.

New Markets

In March, Green Thumb began sales of flower products in Minnesota. After the quarter ended, New Jersey’s Cannabis Regulatory Commission approved seven medical marijuana operators, including Green Thumb, to begin selling adult-use cannabis on April 21; RISE Bloomfield and RISE Paterson were among the first stores to begin adult-use sales on Day One.

“We believe that all our markets will eventually open to adult-use sales—we don’t know exactly when—but we do know that Americans are choosing cannabis for well-being and our trusted family of brands are well-positioned for the future. There is tremendous opportunity in this Great American Growth story, and we believe that the approximately $25 billion legal U.S. cannabis market will have significant growth over the next decade,” concluded Kovler.
Benchmark analyst Mike Hickey said in a Thursday research note that the company’s drop in Ebitda “largely reflected inflation on raw material input and additional compensation for talent throughout the organization. The decrease also reflected pricing headwinds in Pennsylvania, Nevada and Massachusetts. We are cautious on inflationary impacts over the consumer and operating expenses, which could sustain over the medium term.”

Video StaffApril 21, 2022

1min6860

Green Thumb Industries (OTC: GTBIF) began selling adult-use cannabis for the first time at its Rise dispensaries in New Jersey. April 21 was the first day that the state of New Jersey cannabis companies could legally sell recreational marijuana. The company was able to start sales at the Bloomfield and Patterson New Jersey stores. Customers showed up at 6 am on the dot to be able to buy legal recreational marijuana for the first time in their state. With a steel drum player in the parking lot and free donuts, the mood was festive. Even the police seemed to enjoy the party atmosphere.


Debra BorchardtMarch 1, 2022
gti.jpg?fit=850%2C531&ssl=1

4min8290

Green Thumb Industries Inc.  (CSE: GTII) (OTCQX: GTBIF) reported its financial results for the fourth quarter and full-year ended December 31, 2021. GTI delivered total revenue for the fourth quarter of 2021 was $243.6 million, up 37.4% from $177.2 million for the fourth quarter of 2020. Net income for the fourth quarter of 2021 was $22.8 million or $0.10 per basic and diluted share, compared to net income of $22.4 million, or $0.11 per share in the prior year. this also beat the Yahoo Finance average analyst estimates for earnings of $0.08.

For the full year 2021, total revenue was $893.6 million, up 60.5% from the prior year. GTI said that revenue growth was primarily driven by increased scale in its consumer packaged goods and retail businesses, especially in Illinois and Pennsylvania. Key year-over-year performance drivers were the expanded distribution of Green Thumb’s branded products, 10 new store openings, 12 acquired stores, and increased traffic in the Company’s 73 open and operating retail stores. Net income for the full year 2021 was $75.4 million or $0.34 per basic share and $0.33 per diluted share. Green Thumb’s family of consumer brands—RYTHM, Dogwalkers, Incredibles, Beboe, Doctor Solomon’s, and Good Green—were produced, distributed, and available in retail locations across the country.

“Green Thumb’s strong fourth-quarter results reflect our company’s continued deliberate execution. Our team delivered our sixth consecutive quarter of positive GAAP net income, eighth consecutive quarter of positive cash flow from operations and Adjusted Operating EBITDA of $76 million. On a full-year basis, revenue grew 61% to $894 million, GAAP net income more than quadrupled to $75 million and Adjusted EBITDA expanded 71% to $308 million,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “We continue to keep our heads down while focused on executing the business plan. I want to express our gratitude and appreciation to our team, customers, and communities who continue to support us and position us well for the future.”

GTI also noted that this was the eighth consecutive quarter of positive cash flow from operations and that the company had cash of $230.4 million at the end of the quarter. Green Thumb’s fourth quarter included revenue generated from 15 states: California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, and Virginia.

“Everything we have accomplished in 2021 was specifically designed to build long-term value for all of our stakeholders. Cannabis is a complex business but you can rely on us to continue our Enter, Open, Scale strategy to drive value. As I’ve said before, we are still in the early innings of this great American cannabis growth story, and we feel it’s our responsibility to shape this industry, which is being born out of the failed War on Drugs. America is the land of opportunity and we believe the cannabis opportunity should be made available to all Americans, regardless of race, gender or religion. As more states legalize, we hope the industry can include new participants.”

For the full year, GTI reported that total selling, general and administrative expenses were $277.1 million or 31.0% of revenue, an increase from $198.1 million or 35.6% of revenue in the prior year. Decreased operating costs as a percentage of revenue were driven primarily by operating leverage.

 


Debra BorchardtJanuary 3, 2022
hemp-2.jpg?fit=960%2C640&ssl=1

4min10610

There was no rest for the M&A department at Green Thumb Industries Inc. (GTI) (CSE: GTII) (OTCQX: GTBIF) during the holidays. The company announced last week that it closed on an acquisition of Minnesota-based LeafLine Industries. As one of only two licensed cultivators in the Minnesota medical cannabis market, LeafLine is licensed to grow, process, and dispense cannabis directly to patients.

“We are excited to enter the Minnesota medical market and broaden access to cannabis products for Minnesota patients,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “We look forward to caring for LeafLine’s existing patients while ensuring a seamless transition. And looking ahead, we are ready to begin providing patients access to high-quality flower and edible products, both of which have been recently approved. As we kick off 2022, Green Thumb is thrilled to welcome over 100 new team members, a new state and five new retail locations.”

While Minnesota began medical cannabis sales in 2015, the state has been slow to expand its program with only about 29,000 registered active patients according to the Minnesota Department of Health. The state has reported that over 56,000 patients have been approved to date, but many don’t seem to be active in the program. The state currently has 17 qualifying conditions, including chronic pain, multiple sclerosis, post-traumatic stress disorder and seizures. There are only 1,291 approved caregivers. Products available include vape, tinctures and topicals, with flower and edibles coming later in 2022.

According to the Minnesota Legislative Reference Library, “Minnesota has not legalized recreational marijuana, despite legislative proposals to do so. Several bills were introduced in the 2019-2020 session that would legalize or otherwise modify laws around cannabis possession and use in Minnesota, including a proposal to establish a cannabis task force to more closely investigate issues surrounding legalization (see HF717). While the issue generated much discussion, none of the bills to legalize recreational marijuana passed in the 2019-2020 session. Discussion continued in the 2021-2022 session, as bills were again introduced to legalize recreational marijuana (e.g. HF600).”

GTI said in a statement that the acquisition of LeafLine includes a cultivation facility and five open and operating retail locations in Eagan, Hibbing, St. Cloud, St. Paul and Willmar. Green Thumb said it will also maintain the opportunity to open up to three additional retail locations in the state.


Debra BorchardtOctober 5, 2021
shutterstock_511330249-1.jpg?fit=1200%2C1667&ssl=1

4min22660

New York’s Cannabis Control Board is moving quickly to make up for the lost time under the previous administration. In the group’s first meeting since incoming Gov. Hochul stepped in and nominated people for the board, they approved raw cannabis flower as a medical product effective immediately.

Boris Jordan, the founder and chairman of Curaleaf (OTC: CURLF) said on Twitter:

Thank you, NY Gov. Hochul & the Office of Cannabis Management for allowing the sale of whole flower. This decision impacts 151k+ medical patients in NY who will now have access to quality & safe whole flower. Action (not talk) from our new Gov!

In addition to approving flower, the Board also loosened other restrictions.

  • Doctors can approve medical patients
  • 30 day supply increases to 60 day supply
  • $50 registration fee for patients is waived
  • Streamlining dispensation

Currently, New York cannabis law states that adults 21 and older can possess up to three ounces of cannabis or 24 grams of concentrates in New York. The irony is that regular citizens could legally smoke cannabis flower in public, while medical patients weren’t allowed such a form factor.

The meeting was a quick one and lasted roughly 30 minutes. The board members are Tremaine Wright (Cannabis Control Board Chair) , Jessica Garcia, Rueben McDaniel III, Jen Metzger, Adam Perry and Chris Alexander (Executive Director). The meeting also named Jason Starr as the Chief Equity Officer. He served as assistant counsel to former New York Gov. Andrew Cuomo (D) and also worked at the New York Civil Liberties Union.

Patrik Jonsson, Regional President of the Northeast at Curaleaf said, “The expansion of New York’s medical program allowing the sale of whole flower is a very big deal for the thousands of patients affected who now have access to the most cost effective and natural form of the plant. On behalf of Curaleaf and our patient community, I want to thank legislators and the Office of Cannabis Management for their leadership on this issue. This continued evolution of the medical program, which includes expanded qualifying conditions and the removal of application fees, will empower more patients to make choices that work best for their needs. These changes will give New Yorkers access to whole flower that has undergone standardized procedures and testing protocols, ensuring quality and safety. Curaleaf looks forward to expanding our product offerings to best serve our valued patients.” Curaleaf said it could have products on the shelf in November after state testing.

Stocks See Lift

Several of the cannabis companies with large exposure to New York saw stock prices immediately jump on the news. Curaleaf Stock rose as did Green Thumb Industries (GTBIF).


Video StaffSeptember 14, 2021

3min22151

Green Thumb Industries (OTC: GTBIF) is breaking ground on a cultivation center in Warwick NY, a town 54 miles north of New York City. The location is unique because the site used to be a prison that at one time held people incarcerated for cannabis. GTI’s CEO Ben Kovler told the Green Market Report that he appreciates the history of the site and notes the location is key for distribution to New York consumers. He is also pleased that the town has shown its appreciation for GTI’s investment into the facility and the jobs that it will bring.

Here are some fast facts:

The former Warwick medium-security prison, which housed about 1,000 inmates, many for drug offenses, closed just a decade ago.

  • There’s a great full-circle story here – building the modern cannabis campus on the site of a prison that was previously used to incarcerate cannabis users.
  • The $150 million investment made by Green Thumb to refurbish and remodel the site will create hundreds of construction jobs and permanent employment in the region.
  • Senator John Martucci and Assemblymember Karl Brabenec were in attendance at the groundbreaking ceremony
  • The area has a rich history. Before being a prison, the site was also home to the Warwick State Training School for Boys, which was founded in the 1920s. Eleanor Roosevelt and then-Senator Franklin Roosevelt were supporters of the school.

StaffSeptember 1, 2021
Greenstar-scaled.jpg?fit=1200%2C1200&ssl=1

3min28970

Green Thumb Industries Inc. (GTI) (CSE: GTII) (OTCQX: GTBIF) has bought Massachusetts-based GreenStar Herbals, Inc. The value of the transaction was not disclosed. The single state operator owns and operates two adult-use retail locations in Massachusetts. The acquisition also includes a third retail location, set to open in 2021 near Logan International Airport and the Encore Casino.

“Expanding our retail footprint throughout Massachusetts continues our Enter, Open, Scale strategy,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “With this acquisition, we have the maximum number of retail locations in the state, which directly supports the increased production capacity from our acquisition of Liberty Compassion in June. We are excited to work together with the GreenStar team to serve the massive demand for cannabis throughout the Commonwealth.”

In a statement, GTI noted that with the acquisition of GreenStar Herbals Inc., it now has two operational adult-use retail stores in Dracut and Maynard, with a third to open in Chelsea this year, and three medical-use retail stores in Amherst, Boston, and West Springfield. Green Thumb’s existing Rise Amherst store reverted to a medical cannabis store in August.

GreenStar Herbals Chief Executive Officer Thomas Morey added, “We are thrilled to partner with Green Thumb and to continue providing Massachusetts consumers with the highest quality and most diversified cannabis product offerings, along with a premiere in-store retail experience. Green Thumb’s expertise in the industry, along with the company’s values, vision, and emphasis on community impact made this the right partner for our team.”

It may have been slow to be established. but the Massachusetts recreational cannabis market has sold more than $1.5 billion in cannabis products since launching adult-use sales in 2018, according to the state’s Cannabis Control Commission, with daily sales averaging over $3 million so far in 2021. Adult-use cannabis sales in the state have reached nearly $755 million so far in 2021 and are projected to reach $1.2 billion by the end of the year.

Green Thumb’s branded products, including Rythm premium flower and vapes; Dogwalkers brand pre-roll joints; and Incredibles gummies, chocolates, and tarts, are produced in the Commonwealth and available at licensed cannabis dispensaries across Massachusetts. The company began serving medical patients in Massachusetts in 2018 and has two operational cultivation and production facilities in Holyoke and Clinton to serve the growing consumer demand for cannabis.

 


Debra BorchardtAugust 11, 2021
shutterstock_470312240.jpg?fit=960%2C641&ssl=1

5min9110

Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) reported its financial results for the second quarter ending June 30, 2021, with total revenue jumping by 85% to $221.9 million. Green Thumb’s revenue rose 14.1% sequentially and beat the average analyst estimate per Yahoo Finance of $205 million. Net income for the second quarter was $22.1 million or $0.10 per basic and diluted share, compared to a net loss of $12.9 million, or a loss of $0.06 per basic and diluted share in the prior year. This beat the average analyst estimate per Yahoo Finance which was $0.07.

GTI said that the revenue growth was primarily driven by increased scale in the Consumer Packaged Goods and Retail businesses, especially in Illinois and Pennsylvania. Overall performance was driven by the expanded distribution of Green Thumb’s branded products, 10 additional stores, and increased traffic in the Company’s 58 open and operating retail stores. In the second quarter of 2021, Green Thumb generated revenue from all 12 of its markets: California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts, Nevada, New Jersey, New York, Ohio and Pennsylvania. The Company continued to invest in expanding its cultivation and manufacturing capabilities.

“The second quarter continued to be about disciplined execution and the team should be proud of the results. On a year-over-year basis, we grew revenue by 85% to $222 million; more than doubled Adjusted EBITDA to $79 million and continued to deliver positive cash flow. Since the first quarter, we closed three acquisitions, expanding our manufacturing capabilities in Massachusetts and geographic footprint into two new states, Virginia and Rhode Island. These critical steps strengthened our position to distribute our brands to more patients and consumers in existing and new markets,” said Green Thumb Chairman, Founder and Chief Executive Officer Ben Kovler.

In the second quarter 2021, EBITDA was $65.9 million or 29.7% of revenue versus $28.3 million or 23.6% of revenue in the prior year period. Adjusted Operating EBITDA, which excluded non-cash stock-based compensation of $5.7 million and other non-operating expenses of $7.7 million, was $79.3 million or 35.7% of revenue as compared to $35.4 million or 29.6% of revenue for the second quarter 2020. The improvement in EBITDA and Adjusted Operating EBITDA over the prior year period largely reflected revenue growth and increased scale-driven operating leverage from both the Consumer Packaged Goods and Retail businesses. For additional information on these non-GAAP financial measures, see below under “Non-GAAP Financial Information.”

“Finding new and meaningful ways to support the communities we serve is a mission we all share at Green Thumb. We are especially proud of our recently announced Good Green grant program for heroes helping to fight problems created by the failed War on Drugs. Ahead of launching the Good Green brand of products later this year, we are allocating at least $1,300,000 in social equity grants to qualified 501(c)(3) organizations over the next 18 months to jump start this important initiative,” said Kovler.

Expenses increased as total selling, general and administrative expenses for the second quarter were $72.1 million or 32.5% of revenue versus $49.6 million or 41.5% of revenue for the second quarter 2020. Improved operating costs as a percentage of revenue reflected increased operating leverage in the company’s Consumer Packaged Goods and Retail businesses.

“The great American growth story in cannabis is happening–the momentum is undeniable. Consumers demand safe, reliable alternatives for well-being and we are excited to meet their needs with high-quality cannabis experiences. There is still incredible untapped potential in all of our operating regions, and we will continue our strategy to invest in high-return initiatives that prepare us for the growth ahead and future value creation for our stakeholders,” concluded Kovler.


StaffMay 3, 2021
Virginia-2.jpg?fit=960%2C640&ssl=1

3min25780

Green Thumb Industries Inc. (GTI) (OTCQX: GTBIF) is buying Virginia-based  Dharma Pharmaceuticals LLC for an undisclosed amount. the acquisition is expected to close in the second half of 2021. Dharma was the first operator to provide medical products to Virginia’s patients in 2020 and is strategically positioned to scale in the emerging adult-use market. Last month, Virginia became the first Southeastern state in the United States to legalize adult-use cannabis after the Virginia General Assembly approved legislation.

“Change is happening. We are seeing sweeping cannabis reform across the country in favor of expanded access. This momentum has finally reached the first state south of the Mason-Dixon line to ratify adult-use cannabis sales and we are excited to work with the Dharma team in Virginia,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “This industry will create consequential economic opportunities and social change in a part of the country that remains void of legal access to cannabis today. We look forward to serving Virginia’s current medical patients, and future adult-use consumers, while supporting the tremendous positive impact that the legal cannabis industry can have on local communities.”

Currently, Virginia has only legalized medical marijuana and while adult use has been also legalized, sales won’t begin until January 2024. With a population of nearly 8.5 million, Virginia is expected to generate over $1.5 billion in legal cannabis sales, which would create significant tax revenue for the Commonwealth and employ thousands of Virginians.

GTI has been rapidly expanding throughout the U.S. Once this deal is closed, the company will have a presence in 13 markets: California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts, Nevada, New Jersey, New York, Ohio, Pennsylvania, and Virginia. GTI noted that as one of only five licenses in the Virginia medical cannabis market, Dharma is licensed to grow, process, and retail cannabis directly to consumers. In a statement, the company said that the acquisition includes an existing production facility and retail dispensary located in Abingdon, VA. Green Thumb will also have the opportunity to open up to five additional retail locations in the Commonwealth.

Kevin Gibbs, Partner and Head of Operations of Merida Capital Holdings, which is the current majority-equity owner of Dharma, added, “Over the past two years our team has worked hard to introduce the first medical cannabis products to Virginia’s patients. Together with Green Thumb, Dharma’s offering will expand to prepare for the introduction of adult-use sales in the first market in the Southeastern United States.”

 


StaffApril 30, 2021
money-2.jpg?fit=960%2C640&ssl=1

5min15070

GTI

Green Thumb Industries Inc.  (OTCQX: GTBIF) announced that it has closed on a $217 million senior non-brokered private placement financing through the issuance of senior secured notes. GTI said it plans to use the proceeds to retire its existing $105 million senior secured debt due May 2023 and for general working capital purposes as well as various growth initiatives.

“History has taught us that the winners in new industries are those with the lowest cost of capital and the strongest balance sheets,” said GTI Founder and CEO Ben Kovler. “Our successful non-brokered offering (gross=net) was supported by members of the management team in addition to a diverse group of new and existing high-quality, institutional investors who share in our strategic vision and plan to capitalize on the opportunities ahead. This financing represents industry-leading cost of capital in the legal cannabis industry and strengthens our balance sheet. This new capital will allow us to focus on shareholder value creation through strategic investments to scale our existing operations in addition to accretive M&A opportunities.”

The Notes have a maturity date of April 30, 2024 and will bear interest from the date of issue at 7% per annum, payable quarterly, with an option, at the discretion of the company, to extend an additional 12 months. The financing permits the Company to borrow an additional $33 million over the next twelve months. The purchasers of the Notes also received an aggregate of 1,459,043 warrants. Each Warrant is exercisable to purchase one subordinate voting share of GTI at an exercise price of $32.68 per share, for a period of 60 months from the date of issue.

Cansortium

Cansortium Inc.  (OTCQB: CNTMF) has closed a $71 million Senior Secured Term Loan due April 29, 2025. The company plans on using the proceeds to repay convertible debentures that were due in May and strengthen the balance sheet. 

“Today marks a new beginning for Cansortium as we now have the financial flexibility and liquidity that the Company needs to continue growing its attractive asset base,” said Chief Executive Officer Robert Beasley. “Proceeds from the Term Loan have been used to satisfy substantially all of the Company’s existing indebtedness, including repaying $27.1 million of convertible debentures due in May. These actions have resulted in more than $40 million of cash being added to our balance sheet from the Term Loan and the equity offering completed earlier this month. With a strengthened balance sheet and simplified capital structure, we are now firmly positioned to execute our growth and expansion initiatives in our core FloridaPennsylvania, and Michigan markets.”

Neal Hochberg, Cansortium’s Chairman of the Board added, “By extending our debt maturities by four years and bolstering our liquidity, the Company can now focus all of its attention on maximizing value.”

Mr. Beasley added, “Since taking over as CEO in September 2020 , we have made dramatic improvements across key aspects of our business, particularly in Florida where we have significantly increased cultivation yields, introduced new SKUs and form-factors such as edibles, and expanded cultivation and production capacity to better supply our 24 operational dispensaries (expected to increase to 27 by year-end). Florida remains the single largest limited-license cannabis market in the U.S. and we currently have the sixth largest footprint in the state. I am proud of our team’s early accomplishments up to this point and look forward to capitalizing on the many growth opportunities ahead.”

 


Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 9 hours

It’s Time For Institutional Investors to Make a Psychedelics Play

@GreenMarketRpt – 9 hours

Harborside Now Fully Owns Seaside

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.